4.5 Article

Endothelial Cell-Activating Antibodies in COVID-19

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Lipid presentation by the protein C receptor links coagulation with autoimmunity

Nadine Mueller-Calleja et al.

Summary: The study revealed that antiphospholipid antibodies (aPLs) recognize endosomal lysobisphosphatidic acid (LBPA) presented by the endothelial protein C receptor (EPCR), leading to thrombosis induction and inflammatory signaling, contributing to autoimmune pathologies and autoantibody production. Pharmacological intervention targeting the EPCR-LBPA signaling pathway can attenuate these pathologies.

SCIENCE (2021)

Article Multidisciplinary Sciences

Diverse functional autoantibodies in patients with COVID-19

Eric Y. Wang et al.

Summary: COVID-19 patients show increased autoantibody reactivities against immunomodulatory proteins, which may affect immune function and lead to different clinical outcomes.

NATURE (2021)

Article Cardiac & Cardiovascular Systems

Inflammation, Infection and Venous Thromboembolism

Meaghan E. Colling et al.

Summary: The association between inflammation, infection, and venous thrombosis is crucial and can lead to pathological thrombosis. Cells like neutrophils, monocytes, and platelets play essential roles in host defense and thrombus formation. Understanding these mechanisms has advanced knowledge in human physiology and pathophysiology, offering new therapeutic targets for the treatment of thrombosis.

CIRCULATION RESEARCH (2021)

Article Multidisciplinary Sciences

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Sarah Esther Chang et al.

Summary: In hospitalized COVID-19 patients, approximately 50% have detectable autoantibodies primarily targeting autoantigens associated with rare disorders. Additionally, a subset of autoantibodies develop de novo following SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

Article Medicine, Research & Experimental

Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide

Hui Shi et al.

Summary: The study suggests that the FDA-approved polyanionic agent defibrotide can directly engage histones and block their pathological effects on endothelium. In vitro, defibrotide can counteract endothelial cell activation and pyroptosis-mediated cell death triggered by purified NETs or recombinant histone H4, while in vivo, it can stabilize the endothelium and protect against histone-accelerated inferior vena cava thrombosis in mice. Additionally, defibrotide demonstrated direct and tight binding to histone H4, providing insights into the potential role of polyanionic compounds in protecting the endothelium from thromboinflammation in various disease states.

JCI INSIGHT (2021)

Article Medicine, General & Internal

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Dominic Wichmann et al.

ANNALS OF INTERNAL MEDICINE (2020)

Article Cell Biology

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Yu Zuo et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Article Biochemistry & Molecular Biology

Netting neutrophils in autoimmune small-vessel vasculitis

Kai Kessenbrock et al.

NATURE MEDICINE (2009)

Review Immunology

Antiphospholipid syndrome infectious origin

M Blank et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2004)